The German group Hoechst's sales for the first six months of 1996 were down 2% on the like, year-earlier period to 26.1 billion Deutschemarks ($17.7 million). The group said that this was due to the changes in its composition and uneven regional developments.
Pretax profits amounted to 4.3 billion marks, more than twice the year-earlier figure. Operating profits were 2.8 billion marks, up 32%. On a comparable basis, operating profit growth was 18%, reflecting the contribution of the Marion acquisition. Cost-cutting measures at Hoechst Marion Roussel, the diagnostics division, AgrEvo and Hoechst Roussel Vet helped lift profits. The pretax gain was largely attributed to gains from the sale of affiliates and shareholdings.
Turnover in Europe was down 12% on the 1995 first half. However, it was noted that operating business was much better in the second quarter than in the first. In Hoechst's domestic market there was a 23% decline in sales to 2.2 billion marks, half of which was due to spin-offs and divestments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze